Amprion Amplifies Neurological Diagnosis
San Diego Business Journal, February 9, 2023 Parkinson’s disease, Alzheimer’s disease, Lewy Body Dementia – neurological conditions that affect people as they age are often
Menu
San Diego Business Journal, February 9, 2023 Parkinson’s disease, Alzheimer’s disease, Lewy Body Dementia – neurological conditions that affect people as they age are often
HCP Live, December 8, 2023 Alzheimer disease (AD) is defined by the presence of amyloid plaques and tangles in the brain leading to progressive memory
Neurology Live, August 31, 2023 The SYNTap biomarker test (Amprion), first in its class qualitative laboratory developed test, is the only seed amplification assay that
Precision Medicine Online, August 24, 2023 Amprion said on Wednesday that the Center for Alzheimer’s and Related Dementias within the National Institutes of Health’s Intramural
Neurology Live, May 11, 2023 In 2019, the FDA granted Amprion a Breakthrough Device Designation for use of its SYNTap Biomarker Test in assisting for
360Dx, April 26, 2023 A study led by researchers with the Parkinson’s Progression Markers Initiative has found that alpha-synuclein seed amplification assay (αSyn-SAA) testing can
Fierce Biotech, April 18, 2023 A new test could make it possible to diagnose Parkinson’s disease before symptoms appear, paving the way for early intervention.
Everyday Health, April 17, 2023 In a first for Parkinson’s research, a large new study confirmed that a laboratory test analyzing brain and spinal cord
Medscape, April 13, 2023 An alpha-synuclein seed amplification assay (αSyn-SAA) accurately identifies people with Parkinson’s disease (PD), as well as those at risk for PD
CNN Health, April 13, 2023 A lab test that can tell doctors if someone has Parkinson’s disease is a long-sought goal of researchers. Doctors currently
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
Our flagship α-synuclein SAA, SYNTap®, is getting a makeover.
Effective September 9, 2024, SYNTap will be
And stay tuned for the SAAmplify family of panels, coming soon!
